The use of high-sensitivity assays for C-reactive protein in clinical practice

Kiran Musunuru, Brian G. Kral, Roger S. Blumenthal, Valentin Fuster, Catherine Y. Campbell, Ty J. Gluckman, Richard A. Lange, Eric J. Topol, James T. Willerson, Milind Y. Desai, Michael H. Davidson, Samia Mora

Research output: Contribution to journalReview article

Abstract

High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.

Original languageEnglish (US)
Pages (from-to)621-635
Number of pages15
JournalNature Clinical Practice Cardiovascular Medicine
Volume5
Issue number10
DOIs
StatePublished - Aug 20 2008

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Musunuru, K., Kral, B. G., Blumenthal, R. S., Fuster, V., Campbell, C. Y., Gluckman, T. J., Lange, R. A., Topol, E. J., Willerson, J. T., Desai, M. Y., Davidson, M. H., & Mora, S. (2008). The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine, 5(10), 621-635. https://doi.org/10.1038/ncpcardio1322